Conmed Stock EBITDA

CNMD Stock  USD 77.54  2.63  3.51%   
CONMED fundamentals help investors to digest information that contributes to CONMED's financial success or failures. It also enables traders to predict the movement of CONMED Stock. The fundamental analysis module provides a way to measure CONMED's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to CONMED stock.
Last ReportedProjected for Next Year
EBITDA182.2 M191.3 M
The current year's EBITDA is expected to grow to about 191.3 M.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

CONMED Company EBITDA Analysis

CONMED's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

EBITDA

 = 

Revenue

-

Basic Expenses

More About EBITDA | All Equity Analysis

Current CONMED EBITDA

    
  182.19 M  
Most of CONMED's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, CONMED is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

CONMED EBITDA Driver Correlations

Understanding the fundamental principles of building solid financial models for CONMED is extremely important. It helps to project a fair market value of CONMED Stock properly, considering its historical fundamentals such as EBITDA. Since CONMED's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of CONMED's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of CONMED's interrelated accounts and indicators.
0.680.950.530.950.980.940.410.840.960.88-0.390.850.240.370.15-0.920.930.81-0.650.430.850.78-0.57
0.680.510.950.730.580.70.310.820.550.75-0.030.33-0.320.590.21-0.480.440.53-0.350.340.430.390.08
0.950.510.350.830.980.80.440.830.960.9-0.60.970.440.070.3-0.990.990.87-0.780.510.920.81-0.55
0.530.950.350.620.40.550.160.720.390.59-0.020.16-0.560.570.32-0.310.270.3-0.190.250.190.140.23
0.950.730.830.620.880.940.30.760.920.76-0.260.690.050.550.09-0.780.820.69-0.550.220.680.65-0.59
0.980.580.980.40.880.890.440.840.970.89-0.480.930.380.230.17-0.970.970.85-0.690.490.910.83-0.59
0.940.70.80.550.940.890.390.730.890.74-0.160.670.130.59-0.08-0.770.80.7-0.470.30.740.74-0.6
0.410.310.440.160.30.440.390.420.340.49-0.070.340.270.1-0.02-0.430.330.35-0.470.720.470.410.01
0.840.820.830.720.760.840.730.420.780.95-0.460.740.040.240.36-0.840.770.77-0.590.60.740.64-0.12
0.960.550.960.390.920.970.890.340.780.83-0.540.90.360.230.2-0.940.970.84-0.690.350.850.82-0.67
0.880.750.90.590.760.890.740.490.950.83-0.490.840.290.130.35-0.90.850.89-0.750.590.870.77-0.22
-0.39-0.03-0.6-0.02-0.26-0.48-0.16-0.07-0.46-0.54-0.49-0.69-0.360.56-0.760.63-0.6-0.480.54-0.35-0.46-0.390.22
0.850.330.970.160.690.930.670.340.740.90.84-0.690.58-0.120.32-0.980.980.87-0.780.470.920.82-0.58
0.24-0.320.44-0.560.050.380.130.270.040.360.29-0.360.58-0.48-0.09-0.460.490.58-0.570.220.640.68-0.5
0.370.590.070.570.550.230.590.10.240.230.130.56-0.12-0.48-0.49-0.030.080.040.24-0.170.030.05-0.2
0.150.210.30.320.090.17-0.08-0.020.360.20.35-0.760.32-0.09-0.49-0.280.230.16-0.380.280.1-0.030.28
-0.92-0.48-0.99-0.31-0.78-0.97-0.77-0.43-0.84-0.94-0.90.63-0.98-0.46-0.03-0.28-0.98-0.870.75-0.54-0.92-0.830.53
0.930.440.990.270.820.970.80.330.770.970.85-0.60.980.490.080.23-0.980.88-0.740.390.920.84-0.66
0.810.530.870.30.690.850.70.350.770.840.89-0.480.870.580.040.16-0.870.88-0.790.350.950.92-0.47
-0.65-0.35-0.78-0.19-0.55-0.69-0.47-0.47-0.59-0.69-0.750.54-0.78-0.570.24-0.380.75-0.74-0.79-0.42-0.78-0.680.34
0.430.340.510.250.220.490.30.720.60.350.59-0.350.470.22-0.170.28-0.540.390.35-0.420.480.380.22
0.850.430.920.190.680.910.740.470.740.850.87-0.460.920.640.030.1-0.920.920.95-0.780.480.92-0.52
0.780.390.810.140.650.830.740.410.640.820.77-0.390.820.680.05-0.03-0.830.840.92-0.680.380.92-0.59
-0.570.08-0.550.23-0.59-0.59-0.60.01-0.12-0.67-0.220.22-0.58-0.5-0.20.280.53-0.66-0.470.340.22-0.52-0.59
Click cells to compare fundamentals

CONMED EBITDA Historical Pattern

Today, most investors in CONMED Stock are looking for potential investment opportunities by analyzing not only static indicators but also various CONMED's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's ebitda growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of CONMED ebitda as a starting point in their analysis.
   CONMED EBITDA   
       Timeline  
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Competition

CONMED Ebitda

Ebitda

191.3 Million

At present, CONMED's EBITDA is projected to increase significantly based on the last few years of reporting.
According to the company disclosure, CONMED reported earnings before interest,tax, depreciation and amortization of 182.19 M. This is 79.24% lower than that of the Health Care Equipment & Supplies sector and 71.65% lower than that of the Health Care industry. The ebitda for all United States stocks is 95.33% higher than that of the company.

CONMED EBITDA Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses CONMED's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of CONMED could also be used in its relative valuation, which is a method of valuing CONMED by comparing valuation metrics of similar companies.
CONMED is currently under evaluation in ebitda category among its peers.

CONMED ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, CONMED's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to CONMED's managers, analysts, and investors.
Environmental
Governance
Social

CONMED Institutional Holders

Institutional Holdings refers to the ownership stake in CONMED that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of CONMED's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing CONMED's value.
Shares
Geode Capital Management, Llc2024-09-30
693.4 K
Cooke & Bieler Lp2024-09-30
668.8 K
Principal Financial Group Inc2024-09-30
620.7 K
Deerfield Management Co2024-09-30
614.9 K
Morgan Stanley - Brokerage Accounts2024-06-30
577.7 K
Millennium Management Llc2024-06-30
547.6 K
Arrowmark Colorado Holdings, Llc (arrowmark Partners)2024-09-30
501.8 K
Clearbridge Advisors, Llc2024-09-30
496.4 K
Wells Fargo & Co2024-06-30
424.9 K
Blackrock Inc2024-06-30
M
Vanguard Group Inc2024-09-30
3.5 M

CONMED Fundamentals

About CONMED Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze CONMED's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of CONMED using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of CONMED based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether CONMED is a strong investment it is important to analyze CONMED's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact CONMED's future performance. For an informed investment choice regarding CONMED Stock, refer to the following important reports:
Check out CONMED Piotroski F Score and CONMED Altman Z Score analysis.
For information on how to trade CONMED Stock refer to our How to Trade CONMED Stock guide.
You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CONMED. If investors know CONMED will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CONMED listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
2.14
Dividend Share
0.8
Earnings Share
4.22
Revenue Per Share
41.821
Quarterly Revenue Growth
0.04
The market value of CONMED is measured differently than its book value, which is the value of CONMED that is recorded on the company's balance sheet. Investors also form their own opinion of CONMED's value that differs from its market value or its book value, called intrinsic value, which is CONMED's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CONMED's market value can be influenced by many factors that don't directly affect CONMED's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CONMED's value and its price as these two are different measures arrived at by different means. Investors typically determine if CONMED is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CONMED's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.